A Phase 1, Randomized, Open-label, 4-Period Crossover Study in Healthy Subjects to Assess the Food Effect on a Single Dose of JNJ-64417184 Administered as an Oral Solution
Latest Information Update: 03 Sep 2020
At a glance
- Drugs JNJ-64417184 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 01 Sep 2020 Status changed from recruiting to completed.
- 07 Jul 2020 Planned number of patients changed from 32 to 16.
- 07 Jul 2020 Planned End Date changed from 7 Aug 2020 to 4 Aug 2020.